Provided are substituted annellated pyrimidine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and 2-[1-(2,3-Difluorobenzyl)-5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-hydroxy-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one. The compounds stimulate soluble guanylate cyclase and inhibit phosphodiesterase-5. The compounds are useful in the treatment of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular diseases, renal insufficiency, thromboembolic diseases, fibrotic diseases and arteriosclerosis.
